Wuhan Wansheng Biotechnology Safety Rating & Test Results

As of 9 Aug 2026, Finnrick has published 248 independent lab tests of 12 peptides from Wuhan Wansheng Biotechnology: 173 passed and 75 failed under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 22 Jul 2026.

Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.

Purchased from Wuhan Wansheng Biotechnology? Submit a sample to Finnrick for free independent lab testing — results are published publicly.

Are you Wuhan Wansheng Biotechnology? Finnrick offers professional testing services and a public launch program for peptide vendors.

Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.

Wuhan Wansheng Biotechnology peptides tested by Finnrick, rated under the default public methodology.
PeptideFinnrick ratingLab testsLatest test
BPC-15744%1923 Jun 2026
Cagrilintide58%146 May 2026
CJC-129528%76 Mar 2026
GHK-Cu90%2212 Jun 2026
Ipamorelin69%1417 Jul 2026
Melanotan II64%61 Jul 2026
PT-14158%419 Jan 2026
Retatrutide86%7022 Jul 2026
Semaglutide66%522 Jun 2026
TB-50041%923 Jun 2026
Tesamorelin28%2624 Jun 2026
Tirzepatide88%521 Jul 2026